XML 40 R30.htm IDEA: XBRL DOCUMENT
v3.23.3

Financial Instruments (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract] |
Effect of Net Investment Hedges on OCI and the Consolidated Statement of Operations | The effects of the Company’s net investment hedges on OCI and the Condensed Consolidated Statement of Operations are shown below:
| Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income (1) |  | Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing
| Three Months Ended September 30, |  | Nine Months Ended September 30, |  | Three Months Ended September 30, |  | Nine Months Ended September 30,
($ in millions) | 2023 |  | 2022 |  | 2023 |  | 2022 |  | 2023 |  | 2022 |  | 2023 |  | 2022
Net Investment Hedging Relationships |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Foreign exchange contracts | $ | (1) |  |  | $ | (1) |  |  | $ | — |  |  | $ | (47) |  |  | $ | — |  |  | $ | — |  |  | $ | 1 |  |  | $ | (2) |
Euro-denominated notes | (100) |  |  | (250) |  |  | (26) |  |  | (431) |  |  | — |  |  | — |  |  | — |  |  | — |
(1) No amounts were reclassified from AOCL into income related to the sale of a subsidiary.
Summary of Interest Rate Swaps Held | At September 30, 2023, the Company was a party to three pay-floating, receive-fixed interest rate swap contracts designated as fair value hedges of a portion of fixed-rate notes as detailed in the table below.
| September 30, 2023
($ in millions) | Par Value of Debt |  | Number of Interest Rate Swaps Held |  | Total Swap Notional Amount
4.50% notes due 2033 | $ | 1,500 |  |  | 3 |  |  | $ | 750 |
Amounts Recorded on Balance Sheet Related to Fair Value Hedges | The table below presents the location of amounts recorded on the Condensed Consolidated Balance Sheet related to cumulative basis adjustments for fair value hedges:
| Carrying Amount of Hedged Liabilities |  | Cumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount
($ in millions) | September 30, 2023 |  | December 31, 2022 |  | September 30, 2023 |  | December 31, 2022
Balance Sheet Line Item in which Hedged Item is Included |  |  |  |  |  |  |
Long-Term Debt | $ | 743 |  |  | $ | — |  |  | $ | (7) |  |  | $ | — |
Fair Value of Derivatives on a Gross Basis Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments | Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments:
|  | September 30, 2023 |  | December 31, 2022
|  | Fair Value of Derivative |  | U.S. Dollar Notional |  | Fair Value of Derivative |  | U.S. Dollar Notional
($ in millions) |  | Asset |  | Liability |  | Asset |  | Liability |
Derivatives Designated as Hedging Instruments | Balance Sheet Caption |  |  |  |  |  |  |  |  |  |  |
Interest rate swap contracts | Other Noncurrent Liabilities | $ | — |  |  | $ | 8 |  |  | $ | 750 |  |  | $ | — |  |  | $ | — |  |  | $ | — |
Foreign exchange contracts | Other current assets | 321 |  |  | — |  |  | 8,059 |  |  | 220 |  |  | — |  |  | 4,824 |
Foreign exchange contracts | Other Assets | 51 |  |  | — |  |  | 1,746 |  |  | 27 |  |  | — |  |  | 1,609 |
Foreign exchange contracts | Accrued and other current liabilities | — |  |  | 4 |  |  | 680 |  |  | — |  |  | 101 |  |  | 2,691 |
Foreign exchange contracts | Other Noncurrent Liabilities | — |  |  | 1 |  |  | 178 |  |  | — |  |  | 1 |  |  | 91 |
|  | $ | 372 |  |  | $ | 13 |  |  | $ | 11,413 |  |  | $ | 247 |  |  | $ | 102 |  |  | $ | 9,215 |
Derivatives Not Designated as Hedging Instruments | Balance Sheet Caption |  |  |  |  |  |  |  |  |  |  |
Foreign exchange contracts | Other current assets | $ | 229 |  |  | $ | — |  |  | $ | 8,485 |  |  | $ | 186 |  |  | $ | — |  |  | $ | 8,540 |
Foreign exchange contracts | Accrued and other current liabilities | — |  |  | 163 |  |  | 9,910 |  |  | — |  |  | 307 |  |  | 10,926 |
|  | $ | 229 |  |  | $ | 163 |  |  | $ | 18,395 |  |  | $ | 186 |  |  | $ | 307 |  |  | $ | 19,466 |
|  | $ | 601 |  |  | $ | 176 |  |  | $ | 29,808 |  |  | $ | 433 |  |  | $ | 409 |  |  | $ | 28,681 |
Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis | The following table provides information on the Company’s derivative positions subject to these master netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes:
| September 30, 2023 |  | December 31, 2022
($ in millions) | Asset |  | Liability |  | Asset |  | Liability
Gross amounts recognized in the condensed consolidated balance sheet | $ | 601 |  |  | $ | 176 |  |  | $ | 433 |  |  | $ | 409 |
Gross amounts subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet | (138) |  |  | (138) |  |  | (220) |  |  | (220) |
Cash collateral received/posted | (143) |  |  | — |  |  | (66) |  |  | (19) |
Net amounts | $ | 320 |  |  | $ | 38 |  |  | $ | 147 |  |  | $ | 170 |
Location and Amount of Pretax Gains and Losses of Derivatives | The table below provides information regarding the location and amount of pretax gains and losses of derivatives designated in fair value or cash flow hedging relationships:
| Three Months Ended September 30, |  | Nine Months Ended September 30,
($ in millions) | 2023 |  | 2022 |  | 2023 |  | 2022 |  | 2023 |  | 2022 |  | 2023 |  | 2022 |  | 2023 |  | 2022 |  | 2023 |  | 2022
Financial Statement Caption in which Effects of Fair Value or Cash Flow Hedges are Recorded | Sales |  | Other (income) expense, net (1) |  | Other comprehensive income (loss) |  | Sales |  | Other (income) expense, net (1) |  | Other comprehensive income (loss)
| $ | 15,962 |  |  | $ | 14,959 |  |  | $ | 126 |  |  | $ | 429 |  |  | $ | (16) |  |  | $ | (416) |  |  | $ | 45,485 |  |  | $ | 45,453 |  |  | $ | 388 |  |  | $ | 1,576 |  |  | $ | (148) |  |  | $ | (314) |
(Gain) loss on fair value hedging relationships: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Interest rate swap contracts |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Hedged items | — |  |  | — |  |  | (7) |  |  | 1 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (7) |  |  | (13) |  |  | — |  |  | — |
Derivatives designated as hedging instruments | — |  |  | — |  |  | 8 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 8 |  |  | 4 |  |  | — |  |  | — |
Impact of cash flow hedging relationships: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Foreign exchange contracts |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Amount of gain recognized in OCI on derivatives | — |  |  | — |  |  | — |  |  | — |  |  | 247 |  |  | 682 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 375 |  |  | 1,233 |
Increase in Sales as a result of AOCL reclassifications | 45 |  |  | 253 |  |  | — |  |  | — |  |  | (45) |  |  | (253) |  |  | 170 |  |  | 491 |  |  | — |  |  | — |  |  | (170) |  |  | (491) |
Interest rate contracts |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Amount of gain recognized in Other (income) expense, net on derivatives | — |  |  | — |  |  | — |  |  | (1) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (1) |  |  | (2) |  |  | — |  |  | — |
Amount of (loss) gain recognized in OCI on derivatives | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (1) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 13 |  |  | (2) |
(1) Interest expense is a component of Other (income) expense, net.
Income Statement Effects of Derivatives Not Designated as Hedging Instruments | The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:
|  |  | Amount of Derivative Pretax (Gain) Loss Recognized in Income
|  |  | Three Months Ended September 30, |  | Nine Months Ended September 30,
($ in millions) |  |  | 2023 |  | 2022 |  | 2023 |  | 2022
Derivatives Not Designated as Hedging Instruments | Income Statement Caption |  |  |  |  |  |  |  |
Foreign exchange contracts (1) | Other (income) expense, net |  | $ | 60 |  |  | $ | (41) |  |  | $ | 32 |  |  | $ | (77) |
Foreign exchange contracts (2) | Sales |  | — |  |  | (4) |  |  | (3) |  |  | (42) |
(1) These derivative contracts primarily mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates. (2) These derivative contracts serve as economic hedges of forecasted transactions.
Information on Investments in Debt and Equity Securities | Information on investments in debt and equity securities is as follows:
| September 30, 2023 |  | December 31, 2022
| Amortized Cost |  | Gross Unrealized |  | Fair Value |  | Amortized Cost |  | Gross Unrealized |  | Fair Value
($ in millions) | Gains |  | Losses |  | Gains |  | Losses |
Commercial paper | $ | 168 |  |  | $ | — |  |  | $ | — |  |  | $ | 168 |  |  | $ | 498 |  |  | $ | — |  |  | $ | — |  |  | $ | 498 |
U.S. government and agency securities | 67 |  |  | — |  |  | — |  |  | 67 |  |  | 68 |  |  | — |  |  | — |  |  | 68 |
Corporate notes and bonds | 12 |  |  | — |  |  | — |  |  | 12 |  |  | 3 |  |  | — |  |  | — |  |  | 3 |
Total debt securities | $ | 247 |  |  | $ | — |  |  | $ | — |  |  | $ | 247 |  |  | $ | 569 |  |  | $ | — |  |  | $ | — |  |  | $ | 569 |
Publicly traded equity securities (1) |  |  |  |  |  |  | 1,746 |  |  |  |  |  |  |  |  | 1,284 |
Total debt and publicly traded equity securities |  |  |  |  |  |  | $ | 1,993 |  |  |  |  |  |  |  |  | $ | 1,853 |
(1) Unrealized net gains of $61 million and $327 million were recorded in Other (income) expense, net in the third quarter and first nine months of 2023, respectively, on equity securities still held at September 30, 2023. Unrealized net losses of $221 million and $415 million were recorded in Other (income) expense, net in the third quarter and first nine months of 2022, respectively, on equity securities still held at September 30, 2022.
Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis | Financial assets and liabilities measured at fair value on a recurring basis are summarized below:
| Fair Value Measurements Using |  | Fair Value Measurements Using
| Level 1 |  | Level 2 |  | Level 3 |  | Total |  | Level 1 |  | Level 2 |  | Level 3 |  | Total
($ in millions) | September 30, 2023 |  | December 31, 2022
Assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Investments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commercial paper | $ | — |  |  | $ | 168 |  |  | $ | — |  |  | $ | 168 |  |  | $ | — |  |  | $ | 498 |  |  | $ | — |  |  | $ | 498 |
Publicly traded equity securities | 1,306 |  |  | — |  |  | — |  |  | 1,306 |  |  | 1,015 |  |  | — |  |  | — |  |  | 1,015 |
| 1,306 |  |  | 168 |  |  | — |  |  | 1,474 |  |  | 1,015 |  |  | 498 |  |  | — |  |  | 1,513 |
Other assets (1) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
U.S. government and agency securities | 67 |  |  | — |  |  | — |  |  | 67 |  |  | 68 |  |  | — |  |  | — |  |  | 68 |
Corporate notes and bonds | 12 |  |  | — |  |  | — |  |  | 12 |  |  | 3 |  |  | — |  |  | — |  |  | 3 |
Publicly traded equity securities (2) | 440 |  |  | — |  |  | — |  |  | 440 |  |  | 269 |  |  | — |  |  | — |  |  | 269 |
| 519 |  |  | — |  |  | — |  |  | 519 |  |  | 340 |  |  | — |  |  | — |  |  | 340 |
Derivative assets (3) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Forward exchange contracts | — |  |  | 431 |  |  | — |  |  | 431 |  |  | — |  |  | 218 |  |  | — |  |  | 218 |
Purchased currency options | — |  |  | 170 |  |  | — |  |  | 170 |  |  | — |  |  | 215 |  |  | — |  |  | 215 |
| — |  |  | 601 |  |  | — |  |  | 601 |  |  | — |  |  | 433 |  |  | — |  |  | 433 |
Total assets | $ | 1,825 |  |  | $ | 769 |  |  | $ | — |  |  | $ | 2,594 |  |  | $ | 1,355 |  |  | $ | 931 |  |  | $ | — |  |  | $ | 2,286 |
Liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Other liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent consideration | $ | — |  |  | $ | — |  |  | $ | 345 |  |  | $ | 345 |  |  | $ | — |  |  | $ | — |  |  | $ | 456 |  |  | $ | 456 |
Derivative liabilities (3) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Forward exchange contracts | — |  |  | 160 |  |  | — |  |  | 160 |  |  | — |  |  | 402 |  |  | — |  |  | 402 |
Written currency options | — |  |  | 8 |  |  | — |  |  | 8 |  |  | — |  |  | 7 |  |  | — |  |  | 7 |
Interest rate swaps | — |  |  | 8 |  |  | — |  |  | 8 |  |  | — |  |  | — |  |  | — |  |  | — |
| — |  |  | 176 |  |  | — |  |  | 176 |  |  | — |  |  | 409 |  |  | — |  |  | 409 |
Total liabilities | $ | — |  |  | $ | 176 |  |  | $ | 345 |  |  | $ | 521 |  |  | $ | — |  |  | $ | 409 |  |  | $ | 456 |  |  | $ | 865 |
(1) Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans. (2) Balance at September 30, 2023 includes securities with a total fair value of $132 million, which are subject to a contractual sale restriction that expires in July 2024. (3) The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company’s own credit risk, the effects of which were not significant.
Information About the Changes in Liabilities for Contingent Consideration | Summarized information about the changes in the fair value of liabilities for contingent consideration associated with business combinations is as follows:
($ in millions) | 2023 |  | 2022
Fair value January 1 | $ | 456 |  |  | $ | 777 |
Changes in estimated fair value (1) | 6 |  |  | (156) |
Payments | (117) |  |  | (119) |
Other | — |  |  | (3) |
Fair value September 30 (2) | $ | 345 |  |  | $ | 499 |
(1) Recorded in Cost of sales, Research and development expenses, and Other (income) expense, net. Includes cumulative translation adjustments. (2) At September 30, 2023, $255 million of the liabilities relate to the termination of the Sanofi Pasteur MSD joint venture in 2016. As part of the termination, Merck recorded a liability for contingent future royalty payments of 11.5% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate to present value the cash flows. Balance at September 30, 2023 includes $126 million recorded as a current liability for amounts expected to be paid within the next 12 months.

X
- Definition Tabular disclosure of derivative positions subject to master netting arrangements as if they were presented on a net basis. + References No definition available. + Details
Name: | mrk_OffsettingAssetsAndLiabilitiesTableTextBlock
Namespace Prefix: | mrk_
Data Type: | dtr-types1:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -SubTopic 10 -Topic 820 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3 + Details
Name: | us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value. + References No definition available. + Details
Name: | us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4E -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4E Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4C -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4C Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A + Details
Name: | us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4B -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4B + Details
Name: | us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure for fair value hedging instruments of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4C -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4C + Details
Name: | us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of interest rate derivatives, including, but not limited to, the fair value of the derivatives, statement of financial position location, and statement of financial performance location of these instruments. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4C -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4C + Details
Name: | us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4CCC -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4CCC + Details
Name: | us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4C -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4C Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4CC -SubTopic 10 -Topic 815 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4CC + Details
Name: | us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration